Purpose To systematically examine trends and applications of the disease risk score (DRS) as a confounder summary method. Methods We completed a systematic search of MEDLINE and Web of Science W to identify all English language articles that applied DRS methods. We tabulated the number of publications by year and type (empirical application, methodological contribution, or review paper) and summarized methods used in empirical applications overall and by publication year (<2000, ≥2000). Results Of 714 unique articles identified, 97 examined DRS methods and 86 were empirical applications. We observed a bimodal distribution in the number of publications over time, with a peak 1979-1980, and resurgence since 2000. The majority of applications with methodological detail derived DRS using logistic regression (47%), used DRS as a categorical variable in regression (93%), and applied DRS in a non-experimental cohort (47%) or case-control (42%) study. Few studies examined effect modification by outcome risk (23%). Conclusion Use of DRS methods has increased yet remains low. Comparative effectiveness research may benefit from more DRS applications, particularly to examine effect modification by outcome risk. Standardized terminology may facilitate identification, application, and comprehension of DRS methods. More research is needed to support the application of DRS methods, particularly in case-control studies.
INTRODUCTION
Epidemiologic analyses often require investigators to control for many measured confounding variables. Restriction, stratification and matching allow for easily interpretable analysis yet become complex as the number of variables for adjustment increases. 1 Adjustment using multivariable regression techniques has thus become a standard method to control for confounding. In addition to conventional multivariable regression methods that include the exposure and potential confounding variables in a single outcome model, two methods of confounder summary score techniques have been proposed: the exposure propensity score (EPS) and the disease risk score (DRS). [2] [3] [4] [5] [6] [7] [8] EPS reflects patients' exposure probability conditional on measured confounders. This confounder summary score can then be used in place of the individual confounding variables in conventional adjustment methods, such as matching, stratification, weighting, restriction, or as a covariate in the outcome model. 3, 4, 9 Use of EPS has increased exponentially since its introduction in 1983. 2, 3 However, EPS is limited when exposure is rare and can be complicated when studying multiple exposures or multiple exposure levels.
The DRS is the prognostic analogue of the EPS, derived based on the predicted risk of disease outcome and was first proposed methodologically in 1976. 5 Early simulation work published in 1979 concluded that the DRS method may overestimate the effect of confounders and thus bias results. 10 A subsequent simulation published in 1989 concluded that overestimation of confounders may be rare, particularly when applying the DRS as a categorical variable. 11 Recent evidence also identifies that in the setting of a large number of exposed individuals and outcomes, conventional multivariable regression, EPS and DRS methods yield similar results provided that covariates are not highly correlated with exposure. 3, [6] [7] [8] 12 Although the intention of EPS and DRS in summarizing confounders into a single summary score is similar, the logic behind the methods is distinct. EPS models the treatment selection process to balance treatment determinants, similar in concept to randomization in clinical trials. DRS does not share this feature of balancing baseline covariates across treatment groups. Rather, DRS seeks to balance outcome determinants such that baseline outcome risk is similar between treatment groups. In contrast to EPS, DRS is not limited when exposure is rare or categorical, and it can provide a meaningful scale across which investigators can examine effect modification. Despite their advantages and although they were initially proposed before EPS, 5,13-15 DRS methods have received less attention in the epidemiologic literature. 16 We sought to systematically examine trends of the use and application of DRS as a confounder summary method.
METHODS
We conducted a systematic literature search to identify all English language articles that utilized DRS confounder summary score methods in studies of humans. We searched the MEDLINE database from 1965 to May 2011 with keyword terms: "disease$ risk$ score$," "summary$ risk$ score$," "multivariate$ risk$ score$," "confounder$ score$," and "Miettinen$ confounder$ score$"; it was important to include terms in quotations to avoid inclusion of papers that may have used comorbidity indices, such as the Charlson index, 17 or a risk scoring system, such as the Framingham risk score. 18 We then used Web of Science W to perform a citation search to identify papers that referenced seminal DRS method papers 5, 6, 10, 11 and an author search to identify articles published by investigators noted to have frequently used DRS (P. G. Arbogast and W. A. Ray). Two authors (M.T., J.J.G.) reviewed all abstracts to exclude articles that clearly did not meet eligibility criteria. Discrepancies were resolved by agreement. Full text articles were then reviewed to confirm eligibility. The number of eligible publications was plotted by calendar year and type as empirical application, methodological contribution, or review paper. We then focused exclusively on the empirical applications and abstracted author, journal, year of publication, terminology used to describe method, study design, sample size, exposure and outcome variable, number of outcome events, primary analytical methods to derive DRS (statistical method used, data type, number of covariates in model), and how DRS was applied. One author (M.T.) extracted all data, and a second author (J.J.G.) verified all extracted data. The area of study and methods of DRS derivation and application were tabulated overall and stratified by calendar year of publication in print (before or after January 2000).
RESULTS
Of 714 unique articles identified, 97 studies were eligible: 8 methodological contributions, [5] [6] [7] [10] [11] [12] 19, 20 3 review papers, 16, 21, 22 and 86 were empirical applications ( Figure 1 ). We retained one abstract that to our knowledge had not been published in full form 12 and excluded one abstract identified through the search that is now published as a full article. 8, 20 The keyword search identified 173 articles (20 relevant empirical), the major paper citation search identified 338 articles (73 relevant empirical), and the author search identified 320 articles (11 relevant empirical); each method yielded unique empirical papers, and no paper was identified by all three search methods ( Figure 2 ). The empirical studies were published between March 1976 and May 2010 with a bimodal distribution; 32 (37%) articles were published prior to 1990, 15 (17%) in the 1990s, and 39 (45%) since 2000 ( Figure 3 ). Table 1 summarizes the DRS derivation and application methods, with full details presented for each paper in the Supporting Information. The most common terminology used to describe DRS methods included the words and/or combinations of: (i) summary, (ii) confounder, (iii) Miettinen, and (iv) score; and many included disease-specific terminology. Cohort (47%) and case-control (42%) studies were the most common study designs. Studies of cancer risk (27%) and drug effects (24%) were the most common applications. Application focus changed over time, with environmental and social exposures/outcomes (32%) and cancer risk (19%) being the most common before 2000 and drug exposures (46%) and skin cancer risk (36%) dominating since 2000. DRS methods were not clearly reported in up to 15% of empirical papers (Table 1) . Of the empirical papers reporting derivation methods, logistic regression (47%) followed by discriminant analysis (17%) were the most common, with a shift away from discriminant analysis and no study using this method since 2000. The majority of papers did not specify the cohort used to derive DRS (70%). Of the 26 papers with methodological detail, 85% created DRS in an "unexposed" group or subgroup. DRSs were most commonly used as a categorical variable (93%), with a shift from stratification prior to 2000 (89% of applications published before January 2000) to use as a covariate in regression models (63% of applications) since January 2000. The most common number of groups were 3 (28%), 5 (28%), 4 (19%), and 10 (18%).
DISCUSSION
We examined the use of DRS as a confounder summary score method over time and identified a bimodal distribution in DRS application with a peak in 1979-1980 and resurgence since 2000. This bimodal distribution is not surprising given early simulation efforts. In 1976, Miettinen proposed the creation of a multivariate confounder score in the unexposed group to be applied in the full cohort to examine exposure effects adjusted for confounding variables. 5 However, early simulation work by Pike in 1979 concluded that the DRS method may overestimate the effect of confounders and thus bias results. 10 A subsequent simulation by Cook and Goldman published in 1989 concluded that overestimation of confounders may be rare, particularly when applying the DRS as a categorical variable. 11 These results likely rejuvenated interest and confidence in the methodology. The increase since 2000 may also partially relate to the recent increased demand and continued importance of comparative effectiveness research, particularly in the area of pharmacoepidemiology, 9, 109, 110 with 46% of DRS application papers related to drug safety and effectiveness since 2000.
Our results show great variation in DRS application with differences in methods of score derivation, utilization, and naming. The most common method of DRS derivation was originally discriminant analysis and since 2000 has been logistic regression. This follows trends of analyses seen in the last 40 years of health science research, with older studies utilizing discriminant analysis and more recent publications utilizing logistic and other regression analyses. Miettinen's original derivation of the DRS used a discriminant function and discussed Cox, logistic, and linear models as possible alternatives. About half (42%) of empirical studies applied DRS in a case-control study; however, only two methodological contributions have examined DRS using a case-control study design. 10, 12 Pike completed his simulation work that halted wide uptake of the DRS using a case-control study design, 10 and a recent simulation published in abstract form concluded that the DRS may be appropriate in the case-control study when exposure is not highly correlated with its confounders. 12 Use of the propensity score in a case-control has been shown to introduce artificial effect modification and reduce control of confounding. 111 Further methodological work is needed to support DRS utilization in the case-control setting.
DRSs were most commonly used as a categorical variable to control for confounding in the main outcome model. The number of categories varied, with three (28%) and five (28%) groups being the most common. Miettinen recommended that the initial analysis be completed with equal deciles and then adjacent strata combined to create five strata. 5 In many cases, the most clinically relevant number of groups may be three, with risk stratified into low, medium, and high. However, few studies used DRS to communicate results by disease strata (23%). We believe this to be an underutilization of DRS benefits. The added advantage of graphical presentation may allow for easier communication of results and identify effect modification by baseline outcome risk. Stratifying results by disease risk strata may be particularly beneficial in drug effects studies to maximize the benefits and limit harms in patients. Oral bisphosphonates, as an example, are indicated to treat osteoporosis and reduce fracture risk among patients with low bone mineral density and/or major risk factors for fracture. 112 Treating patients at low fracture risk may increase potential harms, with little benefit on fracture risk reduction. Prior evidence identifies little difference in fracture risk reduction between osteoporosis therapies among patients in low risk strata. 7, 113 In the presence of heterogeneous exposure effects, examining the exposure effect across DRS strata allows investigators to examine treatment effect modification by disease (outcome) risk. Once treatment effect heterogeneity has been described, standardization methods such as matching on the DRS, stratifying the Cox proportional hazards model on DRS strata, or another method to adjust for the observed interaction (e.g., by including an interaction term between treatment and DRS in the regression model), may be used if an overall treatment effect estimate is needed. Interestingly, few studies used matching on the DRS as the means to implement DRS, yet matching on EPS is common. 3, 4, 9 Our results show that, where reported, DRSs were most commonly derived in a subgroup of the study population and then applied to the study population at large. These applications are similar to the recommendations made by Miettinen and Cook et al.
5,11
These authors argued the importance of creating the score in the unexposed group so that exposure does not bias the underlying risk of outcome. However, more recent empirical and simulation work has identified that DRS creation in the full cohort may be important in settings where exposure is highly correlated with covariates. 7, 8 In other settings, such as in the context of new therapeutic agents, deriving DRS in an external historical cohort may be advantageous. 114 Further research is needed to understand the relative advantages and disadvantages of different DRS approaches.
Our systematic review is subject to some limitations. First, although we completed a three-step search, we recognize that due to the lack of standardized terminology to describe DRS methods, we may have missed some relevant applications. Indeed, upon discussion of our review with colleagues, five additional DRS applications were identified that were not found through our comprehensive search; three were early applications, [13] [14] [15] and two described DRS as a "propensity score" for the outcome. 115, 116 Although "propensity score" for the outcome is technically correct, this terminology makes the identification and interpretation of the DRS more challenging. Propensity score became an official MeSH keyword heading in 2010, defined as the conditional probability of exposure to a treatment given observed covariates. As DRS applications increase, standardized terminology is recommended. Descriptions such as the "multivariate risk score" and "confounder score" may be confusing and vague, and therefore, we encourage adoption of the recent terminology disease risk score. DRS is descriptive of the technique and unique versus propensity score and may thus minimize possible confusion between these two confounder summary score methods. Despite the limitations of our search strategy, it was interesting to note that all three search strategies (keyword, citation, and author) captured different studies, with only 18 of the 86 studies identified by two methods and no paper identified by all three search methods. The citation search found the largest number of papers, 73 of the 86 papers. Despite potentially missing some applications, we feel that our results and conclusions of the general trends would remain.
Second, given the lack of transparency or detail in how DRS was derived or applied, accurate description of some applications was difficult and supports our recommendation for improved transparency and a move toward standardized terminology in future applications. The great variation in the utilization of DRS highlights the need for further work. Additional simulation research is important to support the best means to utilize DRS, particularly in the case-control setting. Finally, although we summarized derivation methods, we did not consider the process of variable selection or its appropriateness. Considerations for variable selection in DRS are similar to those for EPS and a conventional multivariable regression strategy: risk factors for the outcome of interest that are measured before the start of exposure, and are thus potential confounding variables. 117, 118 In summary, we identified an increase in DRS application yet underutilization of DRS to examine potential effect modification by disease risk. Comparative safety and effectiveness research may benefit from DRS to help target interventions to those who benefit the most. However, more work is needed to guide DRS applications, particularly in the case-control setting. A move toward better transparency in DRS derivation and utilization and standardization of terminology will facilitate DRS application and interpretation. We recommend that future work consider utilizing the terminology disease risk score when describing confounder summary scores derived based on the primary outcome model.
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KEY POINTS
• DRS is a confounder summary score derived based on the probability of disease outcome, and its application may be advantageous over other confounding adjustment techniques when exposure is rare, to study multiple exposures, and to study effect modification by outcome risk.
• Use of DRS confounder summary methods has increased yet remains low. We observed a bimodal distribution in the number of publications over time, with a peak in 1979-1980 and resurgence since 2000. Close to half of empirical applications since 2000 have been associated with pharmacoepidemiology.
• Great variation in DRS applications exists, with differences in methods of score derivation, utilization, and naming.
• There is a general lack of transparency in methods used to derive and apply DRS methods, and few studies used DRS to its full potential by examining effect modification by outcome risk.
• A move toward standardized terminology and providing methodological detail will facilitate DRS utilization and interpretation. We recommend that future work consider adopting the terminology disease risk score when applying confounder summary scores derived based on the probability of disease outcome. Institute, Toronto, ON, for discussions and pointing out DRS applications not identified by our systematic search strategy. Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
